Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by skyhigh123on Mar 15, 2018 1:06pm
117 Views
Post# 27721267

Prometic / CRO / IPF Clinical trial / Experience Needed

Prometic / CRO / IPF Clinical trial / Experience Needed

5 Keys To Establishing Quality Partnerships Between Sponsors And ...

Clinical Leader-Mar. 13, 2018
Forming quality partnerships between pharma's and CROs is essential to executing clinical trials in an efficient manner. There must be a commitment from both the sponsor company and the CRO to form a partnership. By implementing agreements on experience levels of study team staff, focusing on ...


As stated on company NR 

 "This is going to be a multinational study, involving an experienced CRO in the
field to help manage multiple sites across 
the United States, Canada, Australia, the UK and Europe. Our goal is to start patient enrollment mid-year."

Sky


ed  rose quit babbling 
Bullboard Posts